Instrument Inactif

Communiqués Benitec Biopharma Limited Australian S.E.

Actions

BLT

AU000000BLT8

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors	01/07	AQ
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update	13/05	AQ
Benitec Biopharma : Releases Third Quarter 2024 Financial Results and Provides Operational Update - Form 8-K	13/05	PU
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference	01/05	AQ
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study	18/04	AQ
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million	18/04	AQ
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024	09/04	AQ
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update	13/02	AQ
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy	30/11	AQ
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference	17/11	AQ
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update	13/11	AQ
Benitec Biopharma : Material Event - Form 8-K	29/09/23	PU
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update	21/09/23	AQ
Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering	11/08/23	AQ
Benitec Biopharma : Failure to Satisfy Listing Rule - Form 8-K	11/08/23	PU
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering	09/08/23	AQ
Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023	25/07/23	AQ
Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy	26/06/23	AQ
BENITEC BIOPHARMA INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	15/05/23	AQ
Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update	15/05/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Benitec Biopharma Limited Australian S.E.

Actions

BLT

AU000000BLT8

Communiqués

Filtres